ProCE Banner Activity

AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL

Conference Coverage
Slideset

This phase III trial met its primary endpoint, demonstrating that fixed-duration acalabrutinib/venetoclax with or without obinutuzumab significantly improved PFS vs chemoimmunotherapy as first-line therapy for fit patients with CLL. 

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation